Loading
institutionsInstitution
nationales Netzwerk Genomische Medizin Lungenkrebs
aka nNGM, Network Genomic Medicine, NGM Cologne
The German network that gets comprehensive molecular testing to lung cancer patients anywhere in the country, paid for by selective contracts with 66 sickness funds rather than by waiting for the national benefits catalogue.
Overview
The nationale Netzwerk Genomische Medizin Lungenkrebs grew out of the Cologne Network Genomic Medicine, which from 2012 ran comprehensive molecular pathology for referring hospitals on a single diagnostic platform at University Hospital Cologne under Jürgen Wolf and Reinhard Büttner. Deutsche Krebshilfe rolled the model out nationally with one of its largest single grants from 1 April 2018. The network lists 29 centres and more than 500 partner hospitals and specialist practices, and reports on the actionable alterations in non-small-cell lung cancer: KRAS, EGFR, ALK, BRAF, MET, RET, ROS1, HER2 and NTRK.
The financing is the distinctive part. Testing and a second opinion are paid for under selective contracts for besondere Versorgung under section 140a SGB V, which expressly permit terms departing from the ordinary reimbursement rules; 66 cooperating sickness funds covering 94.79 percent of patients had signed as at June 2025, with contracts dating from 2019. A historical cohort linking the nNGM database to AOK claims found median overall survival of 10.5 months against 8.7 for patients treated outside the network (hazard ratio 0.84) and more first-line use of approved targeted drugs; it was funded by the insurers themselves. Coverage is uneven geographically: 668 German hospitals treating 26 percent of lung cancer cases belong to no network at all.
Location
Cologne, DE
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#309 · 22 points (0 Newsweek + 0 NCI + 22 from 11 linked objects) · ranking
- Comprehensive molecular diagnostics for NSCLC
- Second opinion consultations at network centres
- Selective contracts under section 140a SGB V
- nNGM registry (NCT05934032)
Jürgen Wolf
Medical Director, Lung Cancer Group Cologne; Head of Network Genomic Medicine
Lung cancerMolecular diagnostics networksMET and KRAS-targeted therapy
Built the Network Genomic Medicine that brought molecular testing to lung cancer patients across Germany, and led the capmatinib GEOMETRY trial.
Reinhard Büttner
Director, Institute of Pathology, University Hospital Cologne
Molecular pathologyLung cancer genomicsPredictive biomarkers
Molecular pathologist who co-founded Network Genomic Medicine and characterised lung cancer genomes.
Martin Reck
Head of Thoracic Oncology, LungenClinic Grosshansdorf
Lung cancer immunotherapyFirst-line NSCLC therapySmall-cell lung cancer
Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer.
Similar pages
not linked directly; found by shared links- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
Shares ROS1, RET, Next-generation sequencing (NGS), MET.
- Key paperClinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer
Shares ROS1, RET, Next-generation sequencing (NGS), MET.
- Key paperProspective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
Shares ROS1, RET, Next-generation sequencing (NGS), MET.
- CompanyImagene AI
- CompanyLucence
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
- Key paperUpdated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors
Shares ROS1, RET, Next-generation sequencing (NGS), MET.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC